IPMD Point Of Care Device for Testing Infectious Diseases
IPMD, Inc. has formed a research consortium with VA Medical Center Greater Los Angeles Healthcare System to develop a Point of Care Medical Device mainly for people who do not have access to medical facilities near them or cannot afford to have access to infectious disease screening and diagnosis.
Our first focus is to develop a Point of Care System for Gene Phenotyping of Tuberculosis that will be able to identify TB bacteria, its types, and drug resistance and susceptibility. Due to the growing concern of drug-resistant strains, this type of test will provide far more information than other screening methods such as tuberculin skin tests.
According to the WHO, about 80 million people with high danger of TB are not able to access any kind of TB test, and these people will be our first target to help, so this is our one of main driving forces for developing the first mass distribution of POC Devices to test for Tuberculosis.
Currently, there are no low cost Point of Care systems for tuberculosis, so expensive machines and lab facilities must be used. We plan to deploy the Point of Care Tuberculosis Testing Device throughout the world where TB incidence rate is high, so that everyone can receive the test wherever and whenever they want.
IPMD Point of Care Medical Device can also diagnose HIV and its drug resistance, Hepatitis and its drug resistance, Sexually Transmitted Diseases, and other infectious diseases simultaneously.
IPMD patent "Point of Care Medical Device for Detecting Infectious Diseases" is granted on July 11, 2017 from the US Patent Office.